Gastrointestinal cancers
39 public biotech companies we cover are developing treatments for colorectal, pancreatic, gastric, liver and biliary cancer. 16 upcoming catalysts are listed below, with dates as the companies gave them.
Companies
- AbCellera Biologics (ABCL)Thesis Intact
GI cancers
- Adagene (ADAG)Thesis Intact
Colorectal cancer, Hepatocellular carcinoma, Microsatellite stable metastatic colorectal cancer
- Allarity Therapeutics (ALLR)Thesis Intact
Colorectal cancer
- Alpha Tau Medical (DRTS)Thesis Intact
Pancreatic cancer
- ALX Oncology (ALXO)Thesis Challenged
Gastric cancer, Metastatic colorectal cancer
- Arcus Biosciences (RCUS)Thesis Intact
Metastatic pancreatic cancer, Pancreatic ductal adenocarcinoma
- ArriVent BioPharma (AVBP)Thesis Challenged
Gastrointestinal malignancies
- Ascentage Pharma Group Internat (AAPG)Thesis Intact
Gastrointestinal stromal tumor
- Bicycle Therapeutics (BCYC)Thesis Challenged
Pancreatic ductal adenocarcinoma
- Bolt Biotherapeutics (BOLT)Thesis Broken
Gastric and gastroesophageal cancer, Gastric and gastroesophageal junction cancer
- BridgeBio Oncology Therapeutics (BBOT)Thesis Intact
Colorectal cancer, Colorectal cancer and pancreatic ductal adenocarcinoma
- Candel Therapeutics (CADL)Thesis Intact
Pancreatic ductal adenocarcinoma
- Cardiff Oncology (CRDF)Thesis Challenged
Metastatic colorectal cancer, Pancreatic ductal adenocarcinoma
- Cellectar Biosciences (CLRB)Thesis Challenged
Pancreatic cancer
- Coherus Oncology (CHRS)Thesis Challenged
Colorectal cancer, Hepatocellular carcinoma, Esophageal squamous cell carcinoma, Upper gastrointestinal adenocarcinoma
- Compass Therapeutics (CMPX)Thesis Challenged
Colorectal cancer, Biliary tract cancer
- Context Therapeutics (CNTX)Thesis Intact
Colorectal cancer
- CytomX Therapeutics (CTMX)Thesis Intact
Gastric cancer, Colorectal cancer, Biliary tract cancer, Pancreatic ductal adenocarcinoma
- Delcath Systems (DCTH)Thesis Intact
Colorectal cancer, Liver cancer (primary and metastatic), Liver-dominant metastatic colorectal cancer
- Elicio Therapeutics (ELTX)Thesis Broken
Pancreatic ductal adenocarcinoma
- Erasca (ERAS)Thesis Intact
Colorectal cancer, Pancreatic ductal adenocarcinoma
- IDEAYA Biosciences (IDYA)Thesis Intact
Colorectal cancer, Pancreatic ductal adenocarcinoma
- Immuneering (IMRX)Thesis Intact
Pancreatic cancer
- ImmunityBio (IBRX)Thesis Intact
Pancreatic cancer
- Immunocore (IMCR)Thesis Intact
Colorectal cancer
- MAIA Biotechnology (MAIA)Thesis Challenged
Colorectal cancer, Hepatocellular carcinoma
- Moleculin Biotech (MBRX)Thesis Challenged
Pancreatic cancer
- NovoCure (NVCR)Thesis Challenged
Pancreatic cancer
- Nuvectis Pharma (NVCT)Thesis Intact
Pancreatic cancer
- Perspective Therapeutics (CATX)Thesis Intact
Colorectal cancer
- Radiopharm Theranostics (RADX)Thesis Challenged
Pancreatic cancer, Pancreatic ductal adenocarcinoma
- Recursion Pharmaceuticals (RXRX)Thesis Intact
Hepatocellular carcinoma
- Replimune Group (REPL)Thesis Challenged
Biliary tract cancer, Hepatocellular carcinoma
- SELLAS Life Sciences Group (SLS)Thesis Intact
Pancreatic ductal adenocarcinoma
- Summit Therapeutics (SMMT)Thesis Challenged
Colorectal cancer, Gastrointestinal cancers
- Tango Therapeutics (TNGX)Thesis Intact
Pancreatic cancer, Pancreatic ductal adenocarcinoma
- Tonix Pharmaceuticals (TNXP)Thesis Challenged
Gastric cancer, Colorectal cancer, Gastric and colorectal cancer
- TransCode Therapeutics (RNAZ)Thesis Challenged
Colorectal cancer
- Verastem (VSTM)Thesis Intact
Colorectal cancer, Pancreatic cancer, Pancreatic ductal adenocarcinoma
Drug pages
Upcoming catalysts
Firm dates · a specific day set by the company or regulator
Next 30 days
- Oct 25todayARR-217 · Phase 1 interim results · Gastrointestinal malignancies
Estimated timing · a month, quarter, half-year or year-end the company gave
Expected in Q4 2026
- Q4 2026ELI-002 7P · Phase 1 start · Metastatic PDAC · mKRAS · first-line
Expected in H2 2026
- H2 2026ADG126 · Phase 1 start · Colorectal cancer · MSS · 3L+
- H2 2026Casdozokitug · Phase 2 results · Hepatocellular carcinoma · first-line unresectable
- H2 2026Tagmokitug · Phase 1b interim results · Esophageal squamous cell carcinoma · 1L and 2L
- H2 2026ELI-002 · Phase 3 start · PDAC · post-resection · R0
Expected by end of 2026
- end of 2026Varseta-M · Phase 1 results · Advanced colorectal cancer
- year-end 2026RP2 · Phase 2 results · Hepatocellular carcinoma · anti-PD-1/PD-L1 failed
Expected in Q1 2027
- Q1 2027Onvansertib · Phase 3 start (CRDF-005) · Metastatic colorectal cancer · first-line RAS-mutated
Expected by end of March 2027
- Early 2027Alpha DaRT · Results (IMPACT) · Pancreatic cancer · newly diagnosed unresectable, with first-line chemotherapy
Expected in H1 2027
- H1 2027ADG126 · Phase 2 results · Colorectal cancer · MSS · 3L+
- H1 2027Varseta-M · Phase 1 interim results · Advanced colorectal cancer
- H1 2027Varseta-M · Trial start · Advanced colorectal cancer
- H1 2027Quemliclustat · Phase 3 results (PRISM-1) · Pancreatic ductal adenocarcinoma · 1L
- H1 2027Vopimetostat · Phase 3 start · Pancreatic cancer · first-line · MTAP-deleted
Expected by end of June 2027
- mid-2027BBO-11818, BBO-10203 · Results · Colorectal cancer and pancreatic ductal adenocarcinoma · KRAS-mutant